All In Biotech

Drug Trial Radar · NCT04423185

PLATFORM Study of Precision Medicine for Rare Tumors

Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

770

Planned (sponsor's estimate)

Start

Aug 15, 2020

Primary completion

Jul 1, 2026

Study completion Jul 1, 2028

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment.

Conditions

  • Rare Tumor

Interventions

  • Almonertinib 110 MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.

  • Dacomitinib 45 MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.

  • Alectinib 150 MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.

  • Crizotinib 250 MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.

  • Pyrotinib 160/80 MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.

  • Imatinib 400 MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.

  • Niraparib 200/300 MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.

  • Palbociclib 125mgDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.

  • Vemurafenib 240 MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.

  • Sintilimab 100MGDrug

    Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.

  • Atezolizumab 1680 MGDrug

    Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Measured from first dose until confirmed response or progression, assessed up to 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer hospital Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.